Project Grant R01CA298386
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$1.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $954,000 to the University of Pittsburgh to conduct research aimed at understanding how aging promotes the growth of glioblastoma, an aggressive form of brain cancer. The project will leverage insights from aging in the nervous system and the molecular circuitry of cancer stem cells to investigate how aging reprograms the tumor immune microenvironment and cell autonomous nuclear...
This $112,052 federal project grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by the University of Pennsylvania to overcome treatment resistance in gynecological cancers. The key objectives are:
Develop new therapies that exploit genetic vulnerabilities in gynecological cancers with CCNE1 amplification, which are platinum-resistant with poor outcomes. This includes testing drug combinations and identifying biomarkers that...
This $151,000 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to identify essential biomarkers and genes involved in the formation and lifecycle of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to (1) define the critical genes and transition stages required for polyploid cancer cell formation and (2) determine the expression of putative markers of polyploid cancer...
This federal Project Grant award, totaling $552,763, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania.
The grant funds research aimed at assessing the therapeutic potential of newly developed KAT6 inhibitors (KAT6is) as monotherapy and in combination with targeted therapy drugs for the treatment of high-grade...
This National Cancer Institute (NCI) Project Grant award under the Cancer Treatment Research program (CFDA 93.395) provides $530,697 to The Trustees of the University of Pennsylvania to conduct research on the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The overarching objective is to systematically explore the dynamic changes in the regulome induced by PRMT inhibitor treatments in these cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research by Rutgers University to investigate how dysfunctions in the cellular response to mitochondrial stress influence the progression of epithelial ovarian cancer and the orchestration of protective anti-tumor immunity. The $936,746 award, running from December 1, 2024 to November 30, 2029, will leverage the university's unique mouse models, reagents, and extensive ovarian...
This $389,988 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research on the role of tRNA modifications in regulating cancer stem cell (CSC) biology in glioblastoma (GBM). The University of Pittsburgh, the prime awardee, will use mass spectrometry and ribosome profiling techniques to study how altered tRNA modification patterns impact translational reprogramming and drive oncogenic processes in GBM CSCs. The...
The federal Project Grant award of $393,943 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research aimed at defining the cellular and biochemical mechanisms that can be exploited to improve the efficacy and toxicity profile of poly (ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutant cancers. The primary award recipient, Washington University, will lead investigations into how the loss of the nucleosome sliding...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the mechanisms by which chemotherapy used to treat epithelial ovarian cancer can inadvertently activate tumor-associated membrane-anchored serine proteases (MASPs) and promote metastatic disease. The $465,020 award to the University of Maryland, Baltimore aims to 1) define the molecular mechanisms by which combination platinum/taxane...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $150,271 to the University of Maryland Baltimore County (UMBC) to investigate the role of the protein kinase ADCK5 in ovarian cancer. The 2-year project, which began on September 20, 2023, aims to gain fundamental insights into the mechanisms underlying ovarian cancer, the most lethal gynecologic malignancy in the United States. The research seeks to identify potential new...